โ† All deals

Kura Oncology, Inc.

BiotechnologyBiotechnologyPublic CompanyOncology
๐Ÿ“ San Diego, California, United Statesโ€ข Founded 2014
StreetZero Signal 75
Be the first to signal interest

About Kura Oncology, Inc.

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Companyโ€™s pipeline consists of small molecule drug candidates that target cancer signaling pathways, including ziftomenib, a once-daily oral drug candidate targeting the menin-KMT2A protein. It is a public company listed on Nasdaq with headquarters in San Diego, California.

LATEST FUNDINGPrivate Placement
$5.0M
Announced 2026-11-18
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Kura Oncology, Inc..

Free plan includes 3 full deal profiles every month.

Key highlights

  • Raised $150 million in an oversubscribed private placement to fund R&D and operations into 2027.
  • Publicly traded on Nasdaq with total historical funding reported between $63.4M and $1.29B across multiple rounds.
  • Launched Caspian Therapeutics with $50 million financing focused on menin inhibition for diabetes while retaining substantial ownership.
  • Pipeline targets precision oncology with candidates such as ziftomenib for blood cancers and solid tumors.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account